Patents by Inventor Serge Muyldermans

Serge Muyldermans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Virus-like particles and uses thereof
    Patent number: 11453886
    Abstract: The present invention relates to GFLV virus-like particles and the uses thereof in various fields, such as the pharmaceutical, agro, or veterinary areas.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: September 27, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUT FRANCAIS DE LA VIGNE ET DU VIN, VRIJE UNIVERSTEIT BRUSSEL
    Inventors: Serge Muyldermans, Gérard Demangeat, Ahmed Ghannam, Léa Ackerer, Caroline Hemmer, Christophe Ritzenthaler, Vianney Poignavent
  • VIRUS-LIKE PARTICLES AND USES THEREOF
    Publication number: 20200048649
    Abstract: The present invention relates to GFLV virus-like particles and the uses thereof in various fields, such as the pharmaceutical, agro, or veterinary areas.
    Type: Application
    Filed: March 13, 2018
    Publication date: February 13, 2020
    Inventors: SERGE MUYLDERMANS, GÉRARD DEMANGEAT, GHANNAM AHMED, LÉA ACKERER, CAROLINE HEMMER, CHRISTOPHE RITZENTHALER, VIANNEY POIGNAVENT
  • Single domain antibodies capable of modulating BACE activity
    Patent number: 10377834
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: August 13, 2019
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN. K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20180230232
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: January 16, 2018
    Publication date: August 16, 2018
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Anti-influenza antibody
    Patent number: 10023629
    Abstract: The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenza virus infections, and to a pharmaceutical composition comprising the antibody.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: July 17, 2018
    Assignees: VIB VZW, UNIVERSITEIT GENT, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Xavier Saelens, Francisco Miguel Lopez Cardoso, Ann DePicker, Serge Muyldermans
  • Single domain antibodies capable of modulating BACE activity
    Patent number: 9908943
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: March 6, 2018
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • ANTI-INFLUENZA ANTIBODY
    Publication number: 20160376347
    Abstract: The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenzavirusinfections, and to a pharmaceutical composition comprising the antibody.
    Type: Application
    Filed: December 11, 2013
    Publication date: December 29, 2016
    Applicants: VIB VZW, Universiteit Gent, Vrije Universiteit Brussel
    Inventors: Xavier Saelens, Francisco Miguel Lopez Cardoso, Ann DePicker, Serge Muyldermans
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20160237166
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 11, 2013
    Publication date: August 18, 2016
    Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF
    Publication number: 20160052999
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
    Type: Application
    Filed: July 24, 2015
    Publication date: February 25, 2016
    Applicant: VIB vzw
    Inventor: Serge Muyldermans
  • Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
    Patent number: 9156905
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: October 13, 2015
    Assignee: VIB vzw
    Inventors: Serge Muyldermans, Viet Khong Nguyen
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20150071940
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 12, 2015
    Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Single domain antibodies capable of modulating BACE activity
    Patent number: 8568717
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: October 29, 2013
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Vrije Universiteit Brussel
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF
    Publication number: 20120172578
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
    Type: Application
    Filed: August 12, 2011
    Publication date: July 5, 2012
    Applicant: Vlaams Interuniversitair Instituut Voor Biotechnologie
    Inventor: Serge Muyldermans
  • Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
    Patent number: 8097251
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof including an amino acid which is neither a charged amino acid nor a C at position 45, and including an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, the positions determined according to the Kabat numbering.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: January 17, 2012
    Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW
    Inventors: Serge Muyldermans, Karen Silence
  • FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF
    Publication number: 20110251373
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 13, 2011
    Applicant: Vlaams Interuniversitair Instituut Voor Biotechnologie
    Inventor: Serge Muyldermans
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20110091446
    Abstract: The present invention relates to single domain antibodies with a specificity for BACE1. More specifically, the invention provides single variable domain antibodies derived from camelids which bind to BACE1 and are capable of inhibiting the activity of BACE1. Said antibodies can be used for research and medical applications. Specific applications include the use of BACE1 specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: April 3, 2009
    Publication date: April 21, 2011
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF
    Publication number: 20100047241
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
    Type: Application
    Filed: July 7, 2009
    Publication date: February 25, 2010
    Applicant: Vlaams Interuniversitair Instituut Voor Biotechnologies VZW
    Inventor: Serge Muyldermans
  • Recombinant bivalent monospecific immunoglobulin having at least two variable fragments of heavy chains of an immunoglobulin devoid of light chains
    Patent number: 7655759
    Abstract: The present invention relates to fragments, especially variable fragments of immunoglobulins which are by nature devoid of light chains, these fragments being nevertheless capable of exhibiting a recognition and binding activity toward specific antigens. The present invention further relates to the use of such immunoglobulin fragments formed of at least one heavy chain variable fragment or derived therefrom, for therapeutic or veterinary purposes and especially for passive immunotherapy or serotherapy.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: February 2, 2010
    Assignee: Vrije Universiteit Brussel
    Inventors: Raymond Hamers, Serge Muyldermans
  • Immunoconjugates
    Publication number: 20070031430
    Abstract: The present invention relates to novel immunoconjugates that are devoid of light chains and comprise at least one variable domain of a heavy chain antibody. The immunoconjugates of the present invention can be used for the preparation of a medicament to treat tumours.
    Type: Application
    Filed: October 4, 2006
    Publication date: February 8, 2007
    Applicants: Vlaams Interuniversitair Instituut, Vrije Universiteit Brussel
    Inventors: Hilde Revets, Virna Cortez-Retamozo, Serge Muyldermans, Patrick De Baetselier
  • Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
    Publication number: 20070031424
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
    Type: Application
    Filed: June 23, 2006
    Publication date: February 8, 2007
    Applicant: Vlaams Interuniversitair Instituut Voor Biotechnogie VZW
    Inventor: Serge Muyldermans